Bazi Bushen Capsule Alleviates Post-Menopausal Atherosclerosis via GPER1-Dependent Anti-Inflammatory and Anti-Apoptotic Effects

Dan Huang1,2†, Xindong Wang1,2†, Yunhong Zhu1,2, Juexiao Gong1,2, Junqing Liang3, Yanfei Song3, Yiyan Zhang1,2, Linsheng Liu4* and Cong Wei3*

1Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, 2Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China, 3National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, China, 4Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Suzhou, China

Bazi Bushen capsule (BZBS), as a Chinese medicine used to relieve fatigue, has been proven effective for the treatment of atherogenesis through antilipid effects. To investigate the potential mechanism of BZBS in the anti-atherosclerotic effect, Ovx/ApoE-/- mice were applied to investigate the anti-atherosclerotic efficiency and potential mechanism of BZBS. Therapeutic effect was evaluated based on the number of CD68+ and CD3+ cells, the level of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), and the ratio of cleaved caspase-3/caspase-3, as well as increasing ratio of Bcl2/Bax. Human umbilical vein endothelial cells (HUVECs) were chosen to evaluate the role of GPER1. Treatment with BZBS reduced lipid deposition by reducing the numbers of CD68+ and CD3+ cells, the level of ICAM-1 and VCAM-1, and the ratio of cleaved caspase-3/caspase-3, and increasing the ratio of Bcl2/Bax as compared with the control group. In si-GPER1-treated HUVECs, the anti-apoptotic effect of BZBS was decreased. This study revealed that BZBS exhibited a clear effect against atherogenesis via GPER1-dependent anti-inflammatory and anti-apoptotic mechanisms. We believe that this manuscript is informative and useful for researchers pursuing the related alleviation of post-menopausal AS via anti-inflammatory and anti-apoptotic mechanisms.

Keywords: atherosclerosis, bazi bushen capsule, lipid profile, inflammation, apoptosis, GPER1 antagonist

INTRODUCTION

Atherosclerosis (AS) is the basis of cardiovascular diseases (Gaziano et al., 2016; Libby et al., 2011), and cardiovascular diseases are the leading cause of death in women worldwide. Endogenous estrogen has a protective effect against AS in pre-menopausal women. However, in post-menopausal (PM) women, due to the lack of estrogen, the morbidity and mortality associated with AS are greatly increased (Barton, 2013). Despite strong vasculoprotective effects, exogenous estrogen has many side
effects such as thrombosis and tumorigenesis (Schenck-Gustafsson et al., 2011), and clinical treatment of women with estrogen replacement therapy may prevent subclinical AS but has no benefit on cardiovascular disease risk after menopause and later in life (Mcgowan and pottern, 2000; Schenck-Gustafsson et al., 2011). Therefore, estrogen supplementation in PM women for primary and secondary prevention of cardiovascular disease is controversial.

Phytoestrogens (PEs) are a class of non-steroidal compounds that naturally occur in plants, fruits, and vegetables. PEs have structures and molecular weights similar to those of endogenous estrogen, and have estrogen-like effects without estrogen-like side effects (Poluzzi et al., 2014). Many traditional Chinese medicines contain PEs (Zhao et al., 2017; Liang et al., 2019; Yang et al., 2019), which provides new options for PM women looking for safe and effective anti-atherosclerotic drugs. Bazi Bushen capsule (BZBS; an eight-seed kidney-tonifying capsule) was used to relieve fatigue with a compound formula composed of 16 kinds of traditional Chinese medicines (Table 1) BZBS has been proven to improves lipid metabolism (Huang et al., 2020). Fingerprint analysis of BZBS revealed that it contained a variety of PEs, including flavones, coumarins, lignans, and the terpenoid catalpol (Huang et al., 2020).

Estrogen and PEs perform various physiological functions by binding to the corresponding estrogen receptors (Prossnitz and Arterburn, 2015; Rexrode, 2018). The classical estrogen nuclear receptors ERα and ERβ mediate genomic effects by regulating the transcription of specific target genes (Meyer et al., 2011). As a membrane estrogen receptor, the G protein-coupled oestrogen receptor 1 (GPER1) has a rapid nongenomic effect mediated by the second messenger system (Revankar et al., 2005; Meyer et al., 2011). The pathogenesis of AS is complex. Endothelial cells (ECs) inflammation and inflammation-induced endothelial apoptosis are triggers for the occurrence and development of AS (Madhur et al., 2011; Herrero-Fernandez et al., 2019). Moreover, the PM state is characterized by generalized inflammatory activation. Estrogen exerts potent vasculoprotective effects that are partly mediated by inhibiting inflammation and apoptosis (Barton, 2013). GPER1 is expressed in many organs of the body including the arteries (Reslan et al., 2013). In PM mice, GPER1 deficiency exacerbates AS, an effect that is associated with significant vascular inflammation. Administration of G1, a highly selective GPER1 agonist, led to a pronounced decrease in vascular inflammation accompanied by attenuated atherosclerotic plaque formation (Meyer et al., 2014).

In the current study, we aimed to investigate the potential mechanism of BZBS on AS. We investigated the effects of BZBS in an animal model of PM AS ovariectomized (Ovx) ApoE−/− mice. After demonstrating that BZBS has anti-inflammatory and anti-apoptotic effects, we performed an in vitro study to assess the underlying mechanism. Our results revealed that these effects are dependent on the GPER1-mediated inhibition of anti-inflammatory and anti-apoptotic mechanisms.

**MATERIALS AND METHODS**

**Chemicals and Reagents**
BZBS capsules were provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Lot: A1801001, Shijiazhuang, China). A BZBS suspension in 0.5% sodium carboxymethylcellulose (CMC) was administered to mice via intragastric injection. BZBS was weighed and dissolved in serum-free Ham’s F-12K medium. G1 was provided by ApexBio (Houston, TX, United States). As previously described, G1 was dissolved in absolute ethanol to prepare a stock solution of 20 μg/ml and stored in a -20°C freezer. The G1 working solution was diluted 10 times with solvent, and each mouse was injected subcutaneously with 0.2 μg G1 per day (Dennis et al., 2009). The high-fat diet was purchased from Research Diets, Inc. (PE-free, 1.25% cholesterol, 40 kcal% fat, and 0.5% cholic acid, New Brunswick, NJ, United States).

**TABLE 1** | The ratio of the plants present in the preparation of BZBS.

| Plants | Amount in application (ratio) |
|--------|-------------------------------|
| Cuscuta chinensis Lam. [Convolvulaceae; Cuscutae semen] | 250 |
| Lycium barbarum L. [Solanaceae; Lyci cortex] | 23 |
| Schisandra chinensis (Turcz.) Baill. [Schisandraceae; Schisandrae chinensis fructus] | 70 |
| Cnidium monnieri (L.) Cusson [Apiaceae; Cnidii fructus] | 46 |
| Rosa laevigata Michx. [Rosaceae; Rosaie laevigatae fructus] | 35 |
| Rubus chinensis Hu [Rosaceae; Rubi fructus] | 35 |
| Allium tuberosum Rottler ex Spreng. [Amaryllidaceae; Allii tuberosi semen] | 35 |
| Rosa laevigata | 138 |
| Cuscuta chinensis Lam. [Convolvulaceae; Cuscutae semen] | 250 |
| B. juniperus | 25 |
| A. ginseng | 25 |
| C. Kuan | 25 |
| P. sinense | 25 |
| C. deserticola | 25 |
| H. Kelloggii | 25 |
| H. Hippocampus | 21 |
Animal Experiments and Sample Preparation
Fifty C57BL/6J mice and sixty female homozygous ApoE-/- mice (18–22 g) were obtained from GemPharmatech Co., Ltd. (Nanjing, China). The animals were acclimated for three days with a 12 h light-dark cycle with water and food *ad libitum*. The experiments were approved by the Ethics Commission of Animal Care of the Hebei Yiling Chinese Medicine Research Institute with approval number N2018050 (20180711).

Surgical menopause (Ovx/ApoE-/- mice) were induced by ovariectomy under sterile conditions, whereas the C57BL/6J mice (control group, n = 15) only underwent sham surgery (needle threading). After recovering for 7 days, the ApoE-/- mice were then randomized to four groups (n = 15) as described in Table 2. The first group served as the model group, and these animals received a high-fat diet with intragastric (i.g.) injection of the vehicle (0.5% CMC-Na) in 1.4 g/kg/day G1 and high-fat diet, while the low-dose BZBS (2.8 g/kg/day, HD-BZ) groups were treated with BZBS and high-fat diet for 12 weeks.

Cell Experiments
Human umbilical vein endothelial cells (HUVECs) were cultured in Ham’s F-12K medium supplemented with 100 μg/ml heparin, 50 μg/ml endothelial cell growth supplement (EGCS), 10% foetal bovine serum (FBS), and 1% penicillin-streptomycin (P/S) (Procell Life Science & Technology Co., Ltd., Wuhan, China) at 37°C in 5% CO₂. Cells at passages 3–7 were used in subsequent experiments. HUVECs were seeded at a density of 1×10⁵ cells per well into 35-mm dishes. After 24 h, the cells were transfected with 50 nM GPER1 siRNA (CCGACCUGUACUUCAUCAAATT and UUGAUUGAGUACAGGUGCGTT; GenePharma, Shanghai, China) in Gibco Opti-MEM I reduced serum medium with Invitrogen Lipofectamine RNAiMAX transfection reagent. Scrambled siRNA without sequence homology to any known human gene served as the negative control (NC). GPER1 protein levels were measured 40 h post-transfection to evaluate the knockdown efficiency.

To establish an oxidized low-density lipoprotein (Ox-LDL)-induced apoptosis model and assess the protective effect of BZBS, we pretreated transfected HUVECs with 400 μg/ml BZBS in serum-free EC basal medium. The pretreatment started 8 h after transfection, lasted for 12 h and was followed by incubation with Ox-LDL (120 μg/ml, 24 h).

Serum Analysis
The levels of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were quantified by an enzyme-linked immunosorbent assay (ELISA) kit (CUSABIO, Wuhan, China).

Quantification of Atherosclerotic Lesions
For en face quantification of AS, part of the aorta from the descending aorta to the iliac bifurcation was excised, carefully cleaned to remove adherent fat and connective tissue, and mounted en face with oil red O staining solution. To observe atherosclerotic plaques under a microscope, the hearts and proximal aortae were removed, and cross-sections (8 µm serial sections) of the aortic root were stained with haematoxylin-eosin (H&E) and oil red O. Neutral lipids were stained with oil red O. Four cross-sections were analysed from each mouse. Quantification was performed using Image-Pro Plus 6.0 software (Meyer Instruments, Houston, TX, United States).

TUNEL Apoptosis Assay
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labelling) apoptosis assays were performed with the In Situ Cell Death Detection Kit, Fluorescein (Roche, Mannheim, Germany). Cells grow on cover slips were fixed by 4% paraformaldehyde. Protease K working solution was then applied to cover the cells and incubated at 37°C for 25 min. Permeabilization working solution was added to the cover slips, and incubated at room temperature for 20 min. TDT enzyme, dUTP and buffer from the TUNEL kit were mixed at the ratio of 1:5:50 according to the number of slices. After 3% BSA blocking, rabbit polyclonal antibody to CD31 (1:100; Abcam) and goat anti-rabbit IgG (1:100; Abcam, red fluorescence) were used to confirm ECs. The cells were then incubated with a DAPI solution at room temperature for 10 min. Images were obtained using a ZEISS laser scanning confocal microscope.

Immunofluorescence, Quantitative Real-Time PCR analysis, Western Blot Analysis, and Annexin V-FITC/Propidium Iodide Apoptosis Assay
The complete details of immunofluorescence, quantitative real-time PCR analysis, Western blot analysis, and Annexin V-FITC/propidium iodide (PI) apoptosis assay are provided in the Supplementary Material.

### Table 2: Treatment protocol of mice.

| Treatment Regimen | Mice     | Diet     | Dosage in mouse | Treatment Days |
|-------------------|----------|----------|-----------------|----------------|
| Control           | C57BL/6J | Normal   | 0.5% CMC-Na (ig) | 12 weeks       |
| Model             | ApoE-/-  | High-fat | 0.5% CMC-Na (ig) |                |
| G1                | ApoE-/-  | High-fat | 0.2 μg/d G1 (sc) |                |
| HD-BZ             | ApoE-/-  | High-fat | 2.8 g/kg/d (ig) |                |
| LD-BZ             | ApoE-/-  | High-fat | 1.4 g/kg/d (ig) |                |

**Supplementary Material**

- Huang et al. Anti-Atherosclerotic Efficiency of BZBS

---

Frontiers in Pharmacology | www.frontiersin.org 3
June 2021 | Volume 12 | Article 658998
Statistical Analysis
Correlation analysis was performed using IBM SPSS 20.0 software. Statistical analysis was performed by one-way ANOVA. Differences with p-values < 0.05 were considered statistically significant. All results are presented as mean ± SE.

RESULTS
Bazi Bushen Capsule Treatment Hindered the Development of AS in Ovx/ApoE−/− Mice
Both the macroscopic observation of the aortas (Figures 1A,B) and the microscopic images of the aortic roots (Figures 1C,D) revealed that lipid deposition was most severe in the model group. Treatment with G1 or BZBS reduced lipid deposition, as the lesions in the corresponding groups (G1, HD-BZ, and LD-BZ) were narrower than those of the model group (Figures 1A–D). En face analysis of the aortas revealed 29, 26, and 17% reduction in plaque area in the G1, HD-BZ, and LD-BZ groups, respectively, compared with that of the model group (Figures 1A,B), indicating that BZBS has a therapeutic effect against AS induced by estrogen deficiency and a high fat diet. These results support the idea that BZBS exhibits a protective effect against AS.

Bazi Bushen Capsule Treatment Inhibited the Accumulation of Inflammatory Cells in Ovx/ApoE−/− Mice
AS is known to involve an ongoing inflammatory response, with macrophages and T cells playing key roles in the onset and development of this condition (Hansson and Hermansson, 2011). Immunofluorescence analysis of atherosclerotic lesion areas in aortic arches revealed that surgically-induced menopause resulted in a marked accumulation of CD68+ cells (macrophages) and CD3+ cells (T cells) (Figure 2A–C). However, inflammatory cell infiltration in the G1 group and both BZBS groups was significantly reduced (Figure 2A–C). The NF-κB pathway serves as a critical mediator of inflammatory responses by activating the transcription of several pro-inflammatory genes (Taylor and Cummins, 2009). We observed that the p-IκBα/IκBα and p-p65/p65 ratios in the aortas of the model group were significantly higher than those of the control group. G1 and BZBS treatment significantly reduced these ratios, bringing them closer to those of the control group (Figures 2D,E). Activation of the NF-κB pathway leads to the expression of the adhesion proteins VCAM-1 and ICAM-1 (Sun et al., 2020b). The mRNA and protein levels of these adhesion molecules were also assessed. Compared with the control mice, the expression levels of VCAM-1 and ICAM-1 were higher not only in the serum (protein level) but also in the aorta (RNA level) in the high fat diet-fed PM mice. G1 and BZBS reduced the expression of VCAM-1 and ICAM-1 (Figures 2F,G).

Bazi Bushen Capsule Treatment Inhibited Apoptosis in Ovx/ApoE−/− Mice
Inflammation often causes apoptosis. TUNEL apoptosis assays showed that there were significantly fewer apoptotic ECs in the atherosclerotic plaques of the BZBS groups than in those of the model group (Figure 3A). Model mice had markedly lower expression levels (at both the mRNA and protein levels) of the
anti-apoptotic gene, Bcl-2, than control mice, whereas the opposite result was observed for the pro-apoptotic gene, Bax. However, G1 and BZBS attenuated the effects of ovariectomy on both genes, increasing Bcl-2 expression and reducing Bax expression (Figures 3B–D). We also assessed another apoptotic index, the ratio of cleaved caspase-3 to caspase-3. As shown in Figures 3C,D, mice in the model group had higher ratios than control mice, whereas G1 or BZBS treatment reduced the ratio. In other words, BZBS reduced estrogen deficiency-induced apoptosis by regulating Bcl-2, Bax and cleaved caspase-3.
G-Protein-Coupled Estrogen Receptor 1 is a Key Mediator of Bazi Bushen Capsule-Induced Endothelial Protection

Selective GPER1 activation can inhibit postmenopausal AS (Jing et al., 2017). To determine whether GPER1 mediates the endothelial-protective effect of BZBS, GPER1 expression was knocked down in HUVECs by transfection with GPER1-specific siRNA (Figures 4A,B). Apoptosis was induced with 120 μg/ml Ox-LDL. At this concentration, more than half of the cells remained viable (60.04 ± 3.35%, Supplementary Figure S1A). As shown in Supplementary Figure S1B, BZBS increased cell viability, with the increase being most prominent at 400 μg/ml BZBS. As other kinds of vascular cells such as smooth muscle cells were also included in aortic arch atherosclerotic plaques, Figure 3 does not represent the complete results for endothelial cells. Here a similar result was observed with respect to the effect of BZBS on HUVECs.

After the GPER1 gene was knocked down, Bcl2, Bax, cleaved caspase-3 and caspase-3 were almost unchanged between the si-GPER1-control and si-NC-control groups. The Bcl2/Bax ratio decreased slightly (−20.8%, p = 0.088) and the cleaved caspase-3/caspase-3 ratio increased slightly (19.6%, p = 0.158) in the si-GPER1-control group, but the differences were not significant. These results indicate that silencing GPER1 in unstimulated HUVECs may slightly induce apoptosis. Interestingly, after stimulation with Ox-LDL, the Bcl2/Bax ratio in both model groups decreased compared with that in each control group, while the cleaved caspase-3/caspase-3 ratio was significantly increased. BZBS improved these ratios to some extent in the si-GPER1-BZBS group but had a reduced effect compared to that in the si-NC-BZBS group (BZBS upregulated Bcl2/Bax 85.9% in the si-NC group vs. 33.2% in the si-GPER1 group and downregulated cleaved caspase-3/caspase-3 44.8% in the si-NC group vs. 12.0% in the si-GPER1 group; Figures 4C,D). TUNEL and Annexin V-FITC/PI assays also showed that the apoptotic rates in the si-GPER1-control groups were generally higher than those in the corresponding si-NC-control groups (Figures 4E–H). Ox-LDL induced more apoptosis in the si-GPER1 group than in the control group, and the anti-apoptotic effect of BZBS was weaker in si-GPER1 cells than in control cells, suggesting that GPER1 plays a key role in protecting ECs (Figures 4E–H). Although there was no significant difference among the groups in early apoptosis (Supplementary Figure S2A), the same result was found in late apoptosis (Supplementary Figure S2B).

DISCUSSION

The accumulation of lipids in the arterial walls induces AS (Salvayre et al., 2016; Suciu et al., 2018). Sex hormone levels after menopause are associated with increased AS risk in women later in life (Zhao et al., 2018). PEs have been shown to prevent the development of atherosclerotic lesions via lipid metabolism pathways (Chen et al., 2018), and we demonstrated that BZBS contains 11 unique PEs, and improve fatty acid metabolism in the development of atherosclerotic lesions via lipid metabolism pathways (Chen et al., 2018), and we demonstrated that BZBS contains 11 unique PEs, and improve fatty acid metabolism in the clinical state. Although the mouse model used is quite complex, it also successfully simulated the clinically severe hyperlipidemia state after menopause. This animal model is widely used in the hyperlipidemia model of postmenopausal women (Meng et al., 2021b; Sun et al., 2020a). In this study, we aimed to investigate the potential mechanism of BZBS on AS. Lipid deposition was higher after high-fat diet-feeding and spaying ovariectomy. Treatment with BZBS reduced lipid deposition, and BZBS exhibited a clear effect against atherogenesis via GPER1-dependent anti-inflammatory and...
anti-apoptotic mechanisms, which revealed that BZBS exhibited a protective effect against AS. AS is a chronic inflammatory disease, and lipid metabolism mediates AS-related inflammation (Zhu et al., 2018; Wu et al., 2020). In atherosclerotic lesions, macrophages, T lymphocytes, B-lymphocytes, dendritic cells, ECs, and resident immune cells are activated and accumulate, manifesting inflammatory effects (Pyka-Fosciak et al., 2013). Our immunofluorescence analysis demonstrated that BZBS treatment reduced the accumulation of CD68⁺ macrophages and CD3⁺ T cells. Inflammation-activated ECs release pro-inflammatory mediators, including chemokines, pro-inflammatory cytokines, and adhesion molecules (Song et al.,

**FIGURE 4** | Effect of BZBS on the apoptosis of Ox-LDL-induced HUVECs with GPER1 deficiency. (A,B) GPER1 protein levels were measured 40 h post-transfection to evaluate knockdown efficiency. (C,D) Western blots showing Bcl2, Bax, and caspase-3 proteins. (E,F) Annexin V-FLICA/propidium iodide (PI) (G,H) was used to measure the apoptotic rates in the various groups of Ox-LDL-treated HUVECs. The data are presented as the mean ± SD. **p < 0.01 vs. the si-NC control group; ##p < 0.01 vs. the si-NC model group; &&p < 0.01 vs. the si-GPER1 control group; △p < 0.05 vs. the si-GPER1 model group (n = 3).
ECs are the main target of estrogen-mediated vascular protection (Sun et al., 2020a). Estrogen acts as an anti-inflammatory agent by reducing the expression of adhesion proteins via inhibition of the NF-κB pathway (Zhang et al., 2003; Knowlton and Lee, 2012). In this study, the data revealed that BZBS treatment may block the NF-κB signalling pathway, thereby reducing the secretion of adhesion molecules VCAM-1 and ICAM-1 (Figures 2, 5), indicating an anti-inflammatory effect.

EC apoptosis occurs throughout the early stages of AS, and is an important characteristic of this condition (Hort et al., 2014). NF-κB regulates the expression of genes associated with EC apoptosis (Cao et al., 2016). Bcl-2 family members are either anti-apoptotic, such as Bcl-xl and Bcl-2, or pro-apoptotic, such as Bad, Bak, and Bax. The latter proteins are associated with mitochondrial permeability transition pore (MPTP) regulation and the release of cytochrome c (Cyt-c), a critical mitochondrial death factor, resulting in the activation of caspase-9 and caspase-3 and, ultimately, apoptosis (Solesio et al., 2013). Caspase-3 is considered the final executor, as it is indispensable for apoptotic chromatin condensation and DNA fragmentation (Lu et al., 2010). Our data indicated that BZBS markedly inhibited apoptosis, as shown by the upregulation of the anti-apoptotic protein Bcl-2, downregulation of pro-apoptotic Bax, and decreased expression and activity of caspase-3 (Figures 3, 5). This finding was confirmed by immunofluorescence analysis.

As a transmembrane protein, GPER1 contains 375 amino acids and belongs to the G-protein-coupled receptor family. As such, its peptide chain starts with an extracellular N-terminus, traverses the membrane seven times, and ends with an intracellular C-terminus that contains the binding site of a guanosine-binding protein (G protein) (Meyer et al., 2011). Upon binding to estrogen, GPER1 activates several intracellular signal transduction pathways, such as the NF-κB (Du et al., 2018) and caspase-3 signalling pathways (Jiang et al., 2019), decreases the Bax/Bcl-2 ratio (He et al., 2018) and exerts protective effects by inhibiting NF-κB-mediated inflammation and caspase-3-mediated apoptosis. It is well known that PEs exhibit estrogenic activity. The pharmacological effects of some PEs were sensitized by activating GPER1 (Du et al., 2018; Ariyani et al., 2019). In our previous study, 11 unique PEs were identified in BZBS (the relative levels of 11 unique PEs are shown in Table 3, and Figure 6). G1 was selected as a GPER1 agonist because G1 is devoid of uterotrophic activity, similarly to PEs (Meyer et al., 2014). Indeed, our previous study revealed that BZBS did not prevent uterine atrophy in Ovx/ApoE<sup>-/-</sup> mice (Huang et al., 2020). In Ox-LDL-stimulated HUVECs, the Bcl2/Bax ratio decreased compared with that of the control group, while the cleaved caspase-3/caspase-3 ratio was increased significantly after the GPER1 gene was knocked down (Figures 4, 5). TUNEL and Annexin V-FITC/PI assays also showed increased Ox-LDL-mediated apoptosis in the si-GPER1 group, and the anti-apoptotic effect of BZBS was reduced in si-GPER1 cells, suggesting that BZBS exerted a protective effect on ECs (Figure 5) via GPER1-dependent anti-inflammatory and anti-apoptotic mechanisms. In this study, results showed that BSBZ and G1 (GPER agonist) reduce apoptosis in HUVECs through activated GPER, which is contrary to previous observation that

![FIGURE 5](image-url)
GPER activation stimulates cell apoptosis (Gros et al., 2013; Feldman et al., 2014); we speculate that the in vivo situation is likely very different from the in vitro observation (Ding et al., 2009). In addition, the research objects of previous observation are vascular smooth muscle cells. The object of this study is vascular endothelial cells. Some literature studies have shown that the effect of E2 and GPER on endothelial cells is to inhibit apoptosis, while is to promote apoptosis on smooth muscle cells (Kassi et al., 2015; Jing et al., 2017; Wei et al., 2020). In our research, we also found that BSBZ and G1 (GPER agonist) reduce the apoptosis in HUVECs through activated GPER.

However, this study also has some limitations. First, BZBS is a complex molecular mixture, and not all of the contents are completely known. Second, the specific PEs that play major roles have not been determined. Cell membrane chromatography is a very efficient method and was developed to identify bioactive compounds from TCMs (Sun et al., 2020b), this method can be used to characterize the 11 phytoestrogens in BZBS with respect to anti-atherosclerosis effects. Third, GPER1 overexpression was not considered. Fourth, the effects of AS progression through other pathways require further study, such as classic estrogen receptors (ERα, ERβ and several splice variants). We deduced that BZBS can reduce vascular endothelial cell pyroptosis through ERα-mediated activation of autophagy or the following regulation of the expressions of SREBs and SIRT1 to improve atherosclerosis in post-menopausal stage (Chen, et al., 2020; Meng et al., 2021a).

Finally, for extracts already used in humans, it is critical to have a dose–response curve in the experimental setup that includes the usual dose in humans (Heinrich et al., 2020). Current dose usage in our study (1.4 and 2.8 mg/kg/d) was slightly higher than the clinical equivalent dose in mice.

### TABLE 3 | Precision test of relative area.

| Peak | RT (time) | Relative Area | Mean | SD | RSD% |
|------|-----------|---------------|------|----|------|
|      | Test 1    | Test 2        | Test 3 | Test 4 | Test 5 |      |
| 1    | 3.52      | 0.40          | 0.41  | 0.40 | 0.40  | 0.40  |
| 2    | 3.72      | 0.90          | 0.91  | 0.89 | 0.91  | 0.90  |
| 3    | 4.15      | 1.71          | 1.69  | 1.65 | 1.66  | 1.69  |
| 4    | 4.93      | 0.40          | 0.41  | 0.41 | 0.41  | 0.40  |
| 5    | 6.3       | 6.84          | 6.91  | 6.90 | 6.86  | 6.84  |
| 6    | 6.8       | 0.21          | 0.21  | 0.21 | 0.21  | 0.21  |
| 7    | 7.12      | 1.33          | 1.33  | 1.37 | 1.31  | 1.35  |
| 8    | 8.24      | 0.43          | 0.42  | 0.42 | 0.42  | 0.42  |
| 9    | 8.74      | 0.85          | 0.85  | 0.85 | 0.85  | 0.85  |
| 10   | 9.88      | 1.26          | 1.29  | 1.24 | 1.26  | 1.25  |
| 11   | 12.67     | 6.71          | 6.62  | 6.73 | 6.70  | 6.68  |
| 12   | 13.16     | 2.96          | 2.94  | 2.96 | 2.91  | 2.86  |
| 13a  | 14.02     | 4.91          | 4.99  | 4.93 | 4.96  | 4.97  |
| 14a  | 14.47     | 1.17          | 1.16  | 1.21 | 1.16  | 1.17  |
| 15   | 14.73     | 1.03          | 1.03  | 1.04 | 1.02  | 1.03  |
| 16   | 15.33     | 0.45          | 0.45  | 0.46 | 0.45  | 0.45  |
| 17a  | 15.74     | 1.09          | 1.11  | 1.10 | 1.10  | 1.10  |
| 18   | 16.43     | 3.35          | 3.43  | 3.35 | 3.36  | 3.30  |
| 19   | 16.82     | 0.42          | 0.43  | 0.43 | 0.43  | 0.42  |
| 20   | 17.85     | 2.74          | 2.76  | 2.66 | 2.68  | 2.72  |
| 21   | 21.2      | 1.07          | 1.08  | 1.12 | 1.07  | 1.08  |
| 22a  | 27.92     | 1.75          | 1.74  | 1.75 | 1.72  | 1.78  |
| 23   | 28.52     | 6.50          | 6.54  | 6.59 | 6.43  | 6.50  |
| 24a  | 29.31     | 3.98          | 3.89  | 3.85 | 3.81  | 3.81  |
| 25   | 29.64     | 19.31         | 18.73 | 18.96 | 19.40 | 19.31 |
| 26   | 34.71     | 0.16          | 0.17  | 0.16 | 0.16  | 0.16  |
| 27   | 35.07     | 1.69          | 1.77  | 1.72 | 1.70  | 1.72  |
| 28   | 35.71     | 1.32          | 1.36  | 1.36 | 1.34  | 1.34  |
| 29a  | 35.93     | 0.37          | 0.37  | 0.37 | 0.37  | 0.36  |
| 30   | 36.5      | 2.45          | 2.44  | 2.51 | 2.50  | 2.48  |
| 31a  | 37.09     | 3.15          | 3.19  | 3.25 | 3.21  | 3.19  |
| 32a  | 38.05     | 6.68          | 6.74  | 6.63 | 6.66  | 6.73  |
| 33   | 39.02     | 0.42          | 0.43  | 0.42 | 0.42  | 0.42  |
| 34   | 39.71     | 0.66          | 0.65  | 0.67 | 0.66  | 0.66  |
| 35   | 40.17     | 2.05          | 2.09  | 2.11 | 2.05  | 2.04  |
| 36a  | 41.49     | 3.53          | 3.58  | 3.49 | 3.59  | 3.54  |
| 37a  | 43.51     | 2.55          | 2.59  | 2.58 | 2.51  | 2.51  |
| 38a  | 44.75     | 0.67          | 0.65  | 0.66 | 0.67  | 0.66  |
| 39a  | 45.18     | 2.53          | 2.65  | 2.64 | 2.67  | 2.62  |

*Phytoestrogens 13. Isoquercitrin; 14. Hyperoside; 17. Verbascoside; 22. Epimedin A; 24. Icariin; 29. Baohuoside I; 31. Imperatorin; 32. Osthole; 36. Catalpol; 37. Deoxyschizandrin; 39. Schisandrin B.*
(0.7 mg/kg/d). Although the dose is not grossly excessive, the lower dose studies will be needed.

CONCLUSION

In this study, we revealed that BZBS treatment reduced lipid deposition, inhibited inflammatory molecule expression, protected against apoptosis, and decreased atherosclerotic lesion formation in high-fat diet-fed, surgically-induced menopausal mice. We further indicated that the underlying mechanism of these anti-inflammatory and anti-apoptotic effects was mediated by the GPER1 pathway. Our findings indicate that BZBS may prevent AS in postmenopausal women.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The animal study was reviewed and approved by the Ethics Commission of Animal Care of the Hebei Yiling Chinese Medicine Research Institute under approval number N2018050 (20180711). Written informed consent was obtained from the owners for the participation of their animals in this study.

AUTHOR CONTRIBUTIONS

DH, LL, and CW designed the study; DH, XW, Y Zhu, JG, JL, YS, and Y Zhang performed the experiments and collected and analysed data; LL and DH wrote the manuscript.

FUNDING

This work was supported by the National Key Research and Development Program-Modernization of Traditional Chinese Medicine (2017YFC1700501); and the National Natural Science Foundation of China (81973766).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.658998/full#supplementary-material

REFERENCES

Ariyani, W., Miyazaki, W., and Koibuchi, N. (2019). A Novel Mechanism of S-Equol Action in Neurons and Astrocytes: The Possible Involvement of GPR30/GPER1. Int. J. Mol. Sci. 20, 5178. doi:10.3390/ijms2005178
Barton, M. (2013). Cholesterol and Atherosclerosis. Curr. Opin. Lipidol. 24, 214–220. doi:10.1097/MOL.0b013e3283613a94

Cao, W., Hu, C., Wu, L., Xu, L., and Jiang, W. (2016). Rosmarinic Acid Inhibits Inflammation and Angiogenesis of Hepatocellular Carcinoma by Suppression of NF-κB Signaling in H22 Tumor-Bearing Mice. J. Pharmacol. Sci. 132, 131–137. doi:10.1016/j.jpfs.2016.09.003
Chen, J., Yue, J., Liu, Y., Liu, J., Jiao, K., Teng, M., et al. (2018). Blocking of STAT-3/SREBP1-Mediated Glucose-Lipid Metabolism Is Involved in Dietary Phytoestrogen-Inhibited Ovariectomized-Induced Body Weight Gain in Rats. J. Nutr. Biochem. 61, 17–23. doi:10.1016/j.jnutbio.2018.06.009
Chen, Q., Chao, Y., Zhang, W., Zhang, Y., Bi, Y., Fu, Y., et al. (2020). Activation of Estrogen Receptor α (ERα) Is Required for Alisol B23-Acetate to Prevent post-menopausal Atherosclerosis and Reduced Lipid Accumulation. Life Sci. 258, 118030. doi:10.1016/j.lfs.2020.118030

Dennis, M. K., Burai, R., Ramesh, C., Petrie, W. K., Alcon, S. N., Nayak, T. K., et al. (2009). In Vivo effects of a GPR30 Antagonist. Nat. Chem. Biol. 5, 421–427. doi:10.1038/nchembio.168

Ding, Q., Gros, R., Limbird, L. E., Chorazyczewski, J., and Feldman, R. D. (2009). Estradiol-mediated ERK Phosphorylation and Apoptosis in Vascular Smooth Muscle Cells Requires GPR 30. Am. J. Physiology-Cell Physiol. 297, C1178–C1187. doi:10.1152/ajpcell.00185.2009

Du, Z.-R., Feng, X.-Q., Li, N., Qu, J.-X., Feng, L., Chen, L., et al. (2018). G Protein-Coupled Estrogen Receptor Is Involved in the anti-inflammatory Effects of Genistein in Microglia. Pymedicine. 43, 11–20. doi:10.j.phymed.2018.03.039

Feldman, R. D., Gros, R., Ding, Q., Hassain, Y., Ban, M. R., McIntyre, A. D., et al. (2014). A Common Hypofunctional Genetic Variant of GPER Is Associated with Increased Blood Pressure in Women. Br. J. Clin. Pharmacol. 78, 1441–1452. doi:10.1111/bcp.12471

Gazzaniga, T. A., Bitton, A., Anand, S., Ahmed-Gessel, S., and Murphy, A. (2010). Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries. Curr. Probl. Cardiol. 35, 72–115. doi:10.1016/j.cpcardiol.2009.10.002

Gros, R., Ding, Q., Liu, B., Chorazyczewski, J., and Feldman, R. D. (2013). Aldosterone Mediates its Rapid Effects in Vascular Endothelial Cells through GPER Activation. Am. J. Physiology-Cell Physiol. 304, C532–C540. doi:10.1152/ajpcell.00203.2012

Hansson, G. K., and Hermansson, A. (2011). The Immune System in Atherosclerosis. Nature 473, 375–386. doi:10.1038/nature10146

Libby, P., Ridker, P. M., and Hansson, G. K. (2011). Progress and Challenges in Translating the Biology of Atherosclerosis. Nature 473, 317–325. doi:10.1038/ nature10146

Lu, W.-C., Chen, C.-J., Hsu, H.-C., Hsu, H.-L., and Chen, L. (2010). The Adaptor Protein SH2B1B Reduces Hydrogen Peroxide-Induced Cell Death in PC12 Cells and Hippocampal Neurons. J. Mol. Signal. 5, 17. doi:10.1186/1750-2187-5-17

Madvour, M. S., Funt, S. A., Li, L., Vinh, A., Chen, W., Lob, H. E., et al. (2011). Role of Interleukin 17 in Inflammation, Atherosclerosis, and Vascular Function in Apolipoprotein E-Deficient Mice. Arterioscler Thromb. Vasc. Biol. 31, 1565–1572. doi:10.1161/ATVBAHA.111.227629

Mcegwan, J. A., and Pottier, L. (2000). Commentary on the Women’s Health Initiative. Maturitas 34, 109–112. doi:10.1016/S0378-5122(99)00109-7

Meng, Q., Li, Y., Ji, T., Chao, Y., Li, J., Fu, Y., et al. (2021a). Estragon Prevent Atherosclerosis by attenuating Endothelial Cell Pyroptosis via Activation of Estrogen Receptor α-mediated Autophagy. J. Adv. Res. 28, 149–164. doi:10.1016/j.jare.2020.08.010

Meng, Q., Ma, M., Zhang, W., Bi, Y., Cheng, P., Yu, X., et al. (2021b). The Gut Microbiota during the Progression of Atherosclerosis in the Perimenopausal Period Shows Specific Composition Changes and Significant Correlations with Circulating Lipid Metabolites. Gut Microbes 13, 1–27. doi:10.1080/ 19490976.2021.1880220

Meyer, M. R., Clegg, D. J., Prossnitz, E. R., and Barton, M. (2011). Obesity, Insulin Resistance and Diabetes: Sex Differences and Role of Oestrogen Receptors. Acta Physiol. (Oxf). 203, 259–269. doi:10.1111/j.1748-1716.2010.02237.x

Meyer, M. R., Fodette, N. C., Howard, T. A., Hsu, C., Ramesh, C., Daniel, C., et al. (2014). G Protein-Coupled Estrogen Receptor Proteins from Atherosclerosis. Sci. Rep. 4, 7564. doi:10.1038/srep07564

Poluzii, E., Piccinni, C., Raschi, E., Rampa, A., Recanatini, M., and De PONTI, F. (2014). Phytotoxins in Postmenopause: the State of the Art from a Chemical, Pharmacological and Regulatory Perspective. Curr. Med. Chem. 21, 417–436. doi:10.2174/09298673113200660297

Prossnitz, E. R., and Arterburn, J. B. (2015). International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulars. Pharmacol. Rev. 67, 505–540. doi:10.1124/ pr.114.09712

Pyka-Fosciak, G., Javien, J., Gajda, M., Jasek, E., and Litwin, J. A. (2013). Effect of Nebivolol Treatment on Atherosclerotic Plaque Components in apoE-Knockout Mice. J. Physiol. Pharmacol. 64, 745–750.

Reslan, O. M., Yin, Z., do Nascimento, G. R. A., and Khalil, R. A. (2013). Subtype-specific Estrogen Receptor-Mediated Vasoconstrictor Activity in the Cephalic, Thoracic, and Abdominal Vasculature of Female Rat. J. Cardiovasc. Pharmacol. 62, 26–40. doi:10.1097/JCF.0b013e31828ce88a

Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., and Prossnitz, E. R. (2005). A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling. Science 307, 1625–1630. doi:10.1126/science.1106943

Rexrode, K. (2018). Sex Differences in Sex Hormones, Carotid Atherosclerosis, and Stroke. Circ. Res. 122, 17–19. doi:10.1161/CIRCRESAHA.117.312336

Salvayre, R., Negre-Salvayre, A., and Camaré, C. (2016). Oxidative Theory of Atherosclerosis and Antioxidants. Biochimie 121, 289–296. doi:10.1016/j. biochi.2015.12.014

Schend-Szczepanska, K., Brincat, M., Erel, C. T., Gambacciani, M., Lambrinoudaki, I., Moen, M. H., et al. (2011). EMAS Position Statement: Managing the Menopause in the Context of Coronary Heart Disease. Maturitas 68, 94–97. doi:10.1016/j.maturitas.2010.10.005

Soleosio, M. E., Saez-Atienzar, S., Jordan, J., and Galindo, M. F. (2013). 3-Nitropropionic Acid Induces Autophagy by Forming Mitochondrial Permeability Transition Pores rather Than Activating the Mitochondrial Fission Pathway. Br. J. Pharmacol. 168, 63–75. doi:10.1111/j.1476-5381.2012.01994.x

Song, L., Kang, C., Sun, Y., Huang, L., Liu, W., and Qian, Z. (2016). Crocetin Inhibits Lipopolysaccharide-Induced Inflammatory Response in Human Umbilical Vein Endothelial Cells. Cell Physiol. Biochem. 40, 443–452. doi:10.1159/000452559

Suci, C. F., Prete, M., Ruscitti, P., Favino, E., Giacomelli, R., and Perosa, F. (2018). Oxidized Low Density Lipoproteins: The Bridge between Atherosclerosis and Autoimmunity. Possible Implications in Accelerated Atherosclerosis and for Immune Intervention in Autoimmune Rheumatic Disorders. Autoimmun. Rev. 17, 366–375. doi:10.1016/j.autrev.2017.11.028
Sun, B., Yang, D., Yin, Y.-z., and Xiao, J. (2020a). Estrogenic and Anti-inflammatory Effects of Pseudoprotodioscin in Atherosclerosis-Prone Mice: Insights into Endothelial Cells and Perivascular Adipose Tissues. Eur. J. Pharmacol. 869, 172887. doi:10.1016/j.ejphar.2019.172887

Sun, X., Wu, A., Kwan Law, B. Y., Liu, C., Zeng, W., Ling Qiu, A. C., et al. (2020b). The Active Components Derived from Penthorum Chinense Pursh Protect against Oxidative-Stress-Induced Vascular Injury via Autophagy Induction. Free Radic. Biol. Med. 146, 160–180. doi:10.1016/j.freeradbiomed.2019.10.417

Taylor, C. T., and Cummins, E. P. (2009). The Role of NF-κB in Hypoxia-Induced Gene Expression. Ann. N. Y Acad. Sci. 1177, 178–184. doi:10.1111/j.1749-6632.2009.05024.x

Wei, Y., Yuan, P., Zhang, Q., Fu, Y., Hou, Y., Gao, L., et al. (2020). Acacetin Improves Endothelial Dysfunction and Aortic Fibrosis in Insulin-Resistant SHR Rats by Estrogen Receptors. Mol. Biol. Rep. 47, 6899–6918. doi:10.1007/s11033-020-05746-3

Wu, H. M., Ni, X. X., Xu, Q. Y., Wang, Q., Li, X. Y., and Hua, J. (2020). Regulation of Lipid-induced Macrophage Polarization through Modulating Peroxisome Proliferator-activated Receptor-gamma Activity Affects Hepatic Lipid Metabolism via a Toll-like Receptor 4/NF-κB Signaling Pathway. J. Gastroenterol. Hepatol. 35, 1998–2008. doi:10.1111/jgh.15025

Yang, Q., Wang, C., Jin, Y., Ma, X., Xie, T., Wang, J., et al. (2019). Disocin Prevents Postmenopausal Atherosclerosis in Ovariectomized LDLR−/− Mice through a PGC-1α/ERα Pathway Leading to Promotion of Autophagy and Inhibition of Oxidative Stress, Inflammation and Apoptosis. Pharmacol. Res. 148, 104414. doi:10.1016/j.phrs.2019.104414

Zhang, W.-J., Hufnagl, P., Binder, B., and Wojta, J. (2003). Antiinflammatory Activity of Astragaloside IV Is Mediated by Inhibition of NF-κB Activation and Adhesion Molecule Expression. Thromb. Haemost. 90, 904–914. doi:10.1160/TH03-03-0136

Zhao, D., Guallar, E., Ouyang, P., Subramanya, V., Vaidya, D., Ndumele, C. E., et al. (2018). Endogenous Sex Hormones and Incident Cardiovascular Disease in Post-Menopausal Women. J. Am. Coll. Cardiol. 71, 2555–2566. doi:10.1016/j.jacc.2018.01.083

Zhao, Y., Zheng, H. X., Xu, Y., and Lin, N. (2017). Research Progress in Phytoestrogens of Traditional Chinese Medicine. Zhongguo Zhong Yao Za Zhi 42, 3474–3487. doi:10.19540/j.cnki.cjcmm.2017.0135

Zhu, Y., Xian, X., Wang, Z., Bi, Y., Chen, Q., Han, X., et al. (2018). Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules 8, 80. doi:10.3390/biom8030080

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Huang, Wang, Zhu, Gong, Liang, Song, Zhang, Liu and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.